Compare · BSX vs TNDM
BSX vs TNDM
Side-by-side comparison of Boston Scientific Corporation (BSX) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 55.7x TNDM ($1.15B).
- Over the past year, BSX is down 55.3% and TNDM is up 9.7% - TNDM leads by 65.0 points.
- BSX has been more active in the news (5 items in the past 4 weeks vs 4 for TNDM).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Tandem Diabetes Care Inc.
- Price
- -
- -
- Market cap
- $63.97B
- $1.15B
- 1M return
- +1.88%
- -5.72%
- 1Y return
- -55.28%
- +9.73%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest TNDM
- Barclays initiated coverage on Tandem Diabetes Care with a new price target
- Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
- Citigroup reiterated coverage on Tandem Diabetes Care with a new price target
- Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
- William Blair initiated coverage on Tandem Diabetes Care
- EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 4,120 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 5% to 52,040 units (SEC Form 4) to satisfy withholding tax
- PRESIDENT & CEO Sheridan John F converted options into 15,916 shares and covered exercise/tax liability with 8,099 shares, increasing direct ownership by 5% to 160,260 units (SEC Form 4) (for withholding tax)
- EVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 3,014 shares and covered exercise/tax liability with 1,618 shares (SEC Form 4) to satisfy withholding tax
- EVP & Chief Admin. Officer Morrison Susan converted options into 2,827 shares and covered exercise/tax liability with 809 shares, increasing direct ownership by 4% to 52,788 units (SEC Form 4) (tax withholding)
- EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 1,010 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 30,290 units (SEC Form 4) (for withholding tax)